Previous 10 | Next 10 |
Kymera Therapeutics press release (NASDAQ:KYMR): Q4 GAAP EPS of -$0.66 misses by $0.09. Revenue of $15.27M (+19.3% Y/Y) misses by $6.04M. For further details see: Kymera Therapeutics GAAP EPS of -$0.66 misses by $0.09, revenue of $15.27M misses by $6.04M
Completed dose escalation in the KT-474 SAD and MAD portions of Phase 1 trial, with near complete IRAK4 degradation in PBMC and skin, robust ex vivo inhibition of multiple disease-relevant cytokines and favorable safety profile. HS and AD patient cohort data expected in 2H22 IND...
In this clip from "The Pharma & Biotech Show" on Motley Fool Live , recorded on Feb. 2 , Motley Fool contributor Brian Orelli discusses the current drug developments of biotech companies and assesses the strengths and weaknesses of each company as a stock pick. Brian...
The following slide deck was published by Kymera Therapeutics, Inc. in conjunction with this event. For further details see: Kymera Therapeutics (KYMR) Investor Presentation IP - Slideshow
Wells Fargo has initiated Arvinas (ARVN +6.4%) and Kymera Therapeutics (KYMR +4.1%) with overweight ratings. Analyst Derek Archila has price targets as follows: Arvinas, 31% upside based on Wednesday's close; Kymera, ~44% upside. Regarding Arvinas, Archila wrote, "today’s valuati...
BMEZ was one of the best performing funds in 2020, the year it launched as it hit the market at the right time. This success did not carry over to 2021, as it was one of the seemingly few funds to produce losses for the year. It has been an even tougher go as we enter into 2022, a...
WATERTOWN, Mass., Jan. 25, 2022 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced that the Company will participate in th...
WATERTOWN, Mass., Jan. 18, 2022 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced the appointment of John Maraganore, Ph....
Company plans to establish Proof-of-Mechanism and -Biology in patients in immune-inflammatory and oncology indications across its three ongoing clinical programs: IRAK4, IRAKIMiD and STAT3 KT-474 completes dose escalation in healthy volunteer portion of Phase 1 trial, plans ...
WATERTOWN, Mass., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced the Company will present at the virtual...
News, Short Squeeze, Breakout and More Instantly...
Kymera Therapeutics Inc. Company Name:
KYMR Stock Symbol:
NASDAQ Market:
Kymera Therapeutics Inc. Website:
2024-07-12 19:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-09 13:30:00 ET Shares of Kymera Therapeutics (NASDAQ: KYMR) were soaring 18.4% higher as of 11:28 a.m. ET on Tuesday. The big jump came after the clinical-stage biopharmaceutical company announced on Monday that its partner, Sanofi , plans to expand the ongoing phase 2 s...
WATERTOWN, Mass., July 09, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced that the Company will participate in a fireside ...